Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER vs DEGARELIX ACETATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Treatment of advanced prostate cancer
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Terminal elimination half-life is approximately 43-73 days after subcutaneous administration, reflecting slow release from the depot formulation.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Hepatic via hydrolysis of the acetate ester; no significant CYP450 involvement.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Renal elimination accounts for approximately 20-30% of the dose as unchanged drug; fecal elimination accounts for 70-80% primarily as metabolites.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
Approximately 90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Approximately 1 L/kg, indicating extensive distribution into tissues.
100% intravenous; not administered by other routes.
Subcutaneous: approximately 100% for the depot formulation; not available orally due to peptide degradation.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
No dose adjustment required for GFR ≥15 m L/min. Insufficient data for GFR <15 m L/min or dialysis; use caution.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe impairment (Child-Pugh C).
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Safety and efficacy not established in pediatric patients; no recommended dosing.
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
No specific dose adjustment required; similar efficacy and safety observed in elderly patients (≥65 years) compared to younger adults.
Not applicable; no FDA boxed warning exists for this product.
None
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Hypersensitivity reactions including anaphylaxis and angioedema,QT interval prolongation,Laboratory test interference with gonadotropin and gonadal steroid assays,Injection site reactions including pain and erythema,Bone density loss,Hyperglycemia and increased risk of diabetes
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
Hypersensitivity to degarelix or any component of the formulation,Pregnancy (potential fetal harm)
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
No specific food interactions have been identified. Degarelix is administered parenterally and does not interact with dietary components. Avoid grapefruit juice if concurrent QT-prolonging drugs are used, but not a direct interaction with degarelix.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential for fetal androgen deprivation leading to ambiguous genitalia in male fetuses.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No data available on excretion in human milk; potential for serious adverse effects in nursing infants; discontinue breastfeeding or discontinue drug.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
No dose adjustments are applicable as degarelix is contraindicated in pregnancy; therapy must be discontinued if pregnancy occurs.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
Degarelix acetate is a Gn RH antagonist used for advanced prostate cancer. It provides rapid testosterone suppression without the initial testosterone surge seen with Gn RH agonists. Monitor serum testosterone and PSA levels; castrate levels (<50 ng/d L) typically achieved within 3 days. Injection site reactions are common; rotate injection sites (abdomen, thigh, buttock). Avoid in patients with known QT prolongation or concurrent QT-prolonging drugs. Contraindicated in women and children.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
Degarelix is given as a subcutaneous injection by a healthcare provider every month (or every 2 months for maintenance dose) to treat advanced prostate cancer.,Do not miss scheduled injections because consistent dosing is needed to keep testosterone levels low.,Common side effects include injection site pain, redness, or swelling; hot flashes; increased liver enzymes; and weight gain.,Report signs of allergic reaction (rash, itching, difficulty breathing) or prolonged QT interval (fainting, palpitations) to your doctor immediately.,Degarelix may cause bone thinning; discuss calcium and vitamin D supplementation with your doctor.,This drug can cause harm to a fetus; not for use in women or children.
No interactions on record
"Asenapine, a second-generation antipsychotic, is associated with dose-dependent QTc interval prolongation due to its inhibitory effects on cardiac potassium channels (specifically IKr). Degarelix, a GnRH antagonist used in prostate cancer, may also cause QTc prolongation, likely through hormonal suppression mechanisms. Coadministration can result in additive QTc prolongation, increasing the risk of torsade de pointes and other ventricular arrhythmias, especially in patients with pre-existing risk factors."
"Dolasetron, a 5-HT3 receptor antagonist, is known to cause dose-dependent prolongation of the QT interval by blocking cardiac potassium channels. When coadministered with Degarelix, a GnRH receptor antagonist that also reduces testosterone levels and can induce QT prolongation via electrolyte disturbances (e.g., hypokalemia, hypomagnesemia) or direct cardiac effects, the risk of additive QT prolongation is increased. This may lead to a higher propensity for torsade de pointes and other ventricular arrhythmias, particularly in patients with pre-existing risk factors."
"Cabazitaxel is a taxane antineoplastic agent that undergoes extensive hepatic metabolism via CYP3A4/5 and is a substrate of P-glycoprotein. Degarelix, a GnRH antagonist, has no known direct metabolic interaction with Cabazitaxel but may theoretically increase the risk of QT prolongation when combined with other drugs. However, the baseline description is vague; the interaction is not well-established and possibly refers to additive myelosuppression or cardiovascular effects from overlapping toxicities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER vs DEGARELIX ACETATE, answered by our medical review team.
ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. DEGARELIX ACETATE is a GnRH antagonist that works by Gonadotropin-releasing hormone (Gn RH) receptor antagonist; competitively and reversibly binds to Gn RH receptors in the anterior pituitary, rapidly suppressing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing testosterone production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER and DEGARELIX ACETATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. The standard adult dose of DEGARELIX ACETATE is: Subcutaneous injection: 240 mg loading dose (two 120 mg injections) on day 1, followed by 80 mg every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER and DEGARELIX ACETATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. DEGARELIX ACETATE is classified as Category C. Category X: Contraindicated in pregnancy. First trimester: Risk of spontaneous abortion and congenital anomalies due to hormonal disruption. Second and third trimesters: Potential . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.